Difference between revisions of "Template:Drug Development and Design"
(Create page) |
(redo) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 19: | Line 19: | ||
4:30 Intermission | 4:30 Intermission | ||
| + | |||
| + | 4:35 198 ''Optimization of the β5 Potency and Cellular Activity of a Series of Non-Covalent Dipeptide Inhibitors of the Human20S Proteasome Guided by X-ray Crystallography''. '''Christopher Blackburn''', Cynthia Barrett, Jonathan Blank, Nancy Bump, Frank Bruzzese, Larry Dick, Paul Fleming, Khris Garcia, Paul Hales, Lee Herman, Matt Jones, Jane Liu, Darshan Sappal, Mike Sintchak, Chris Tsu and Ken Gigstad, Millennium Pharmaceuticals, The Takeda Oncology Company | ||
| + | |||
| + | 4:55 199 ''Antimicrobial and Antitumor Properties of Silver Carbene Complexes Encapsulated in Nanoparticles''. '''Wiley J. Youngs''', Amanda R. Knapp, Matthew J. Panzner and Claire A. Tessier, University of Akron | ||
| + | |||
| + | <s>5:15 200 ''Synthesis, Characterisation and In-Vitro Cytotoxic Activity of Some Ru(II) Complexes''. '''Sreekanth Thota'''1, Subhas Somalingappa Karki2 and Erik de Clercq3, (1)S.R. College of Pharmacy, (2)KLE Academy of Higher Education and Research, (3)Rega Institute of Medical Research</s> The final presentation was canceled, because Dr. Thota did not attend the meeting. | ||
| + | |||
| + | 5:35 Concluding Remarks | ||
[[Category:Program content]] | [[Category:Program content]] | ||
Latest revision as of 22:00, 5 June 2010
Thursday, June 3, 1:00 PM - 5:40 PM
- Drug Development and Design
- Kellas 104
Organizer/Presider: Jason Herr
1:00 Introductory Remarks
1:05 193 Discovering Drugs, Tools and Interesting Chemical Properties. Steven R. LaPlante, Boehringer Ingelheim (Canada) Ltd.
1:45 194 Novel 5-HT3 Receptor Modulators for the Potential Treatment of Irritable Bowel Syndrome. David D. Manning1, Christopher L. Cioffi1, Kristen N. Ryan1, Alexander Usyatinsky1, Kevin Fitzpatrick1, Carla Hassler1, Svetlana Dobritsa1, Cheng Guo1, Liaqat Masih1, Zhenjun Zhang1, Sok Hui Choo1, Jonathan D. Wierschke1, William G. Earley1, Peter R. Guzzo1, Marlene L. Cohen2, Amy S. Butler3, Catherine A. Brady3 and Nicholas M. Barnes3, (1)AMRI, (2)Creative Pharmacology Solutions LLC, (3)Celentyx Ltd.
2:25 195 Rethinking Natural Products in the Light of New Synthetic Methodologies. Mark Behnke, MLBehnke Consulting
3:05 Intermission
3:10 196 Drug Development and Design: Fundamental Concepts in Scaling from Milligrams to Kilograms. Robert Norrie, AMRI
3:50 197 Recent Development in Catalysis at BI. Wenjun Tang, Boehringer Ingelheim Pharmaceuticals Inc
4:30 Intermission
4:35 198 Optimization of the β5 Potency and Cellular Activity of a Series of Non-Covalent Dipeptide Inhibitors of the Human20S Proteasome Guided by X-ray Crystallography. Christopher Blackburn, Cynthia Barrett, Jonathan Blank, Nancy Bump, Frank Bruzzese, Larry Dick, Paul Fleming, Khris Garcia, Paul Hales, Lee Herman, Matt Jones, Jane Liu, Darshan Sappal, Mike Sintchak, Chris Tsu and Ken Gigstad, Millennium Pharmaceuticals, The Takeda Oncology Company
4:55 199 Antimicrobial and Antitumor Properties of Silver Carbene Complexes Encapsulated in Nanoparticles. Wiley J. Youngs, Amanda R. Knapp, Matthew J. Panzner and Claire A. Tessier, University of Akron
5:15 200 Synthesis, Characterisation and In-Vitro Cytotoxic Activity of Some Ru(II) Complexes. Sreekanth Thota1, Subhas Somalingappa Karki2 and Erik de Clercq3, (1)S.R. College of Pharmacy, (2)KLE Academy of Higher Education and Research, (3)Rega Institute of Medical Research The final presentation was canceled, because Dr. Thota did not attend the meeting.
5:35 Concluding Remarks
